Literature DB >> 18498117

Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC.

R M Overmeer1, F E Henken, P J F Snijders, D Claassen-Kramer, J Berkhof, T J M Helmerhorst, D A M Heideman, S M Wilting, Y Murakami, A Ito, C J L M Meijer, R D M Steenbergen.   

Abstract

We previously showed that silencing of TSLC1, recently renamed CADM1, is functionally involved in high-risk HPV-mediated cervical carcinogenesis. CADM1 silencing often results from promoter methylation. Here, we determined the extent of CADM1 promoter methylation in cervical (pre)malignant lesions and its relation to anchorage-independent growth and gene silencing to select a CADM1-based methylation marker for identification of women at risk of cervical cancer. Methylation-specific PCRs targeting three regions within the CADM1 promoter were performed on high-risk HPV-containing cell lines, PBMCs, normal cervical smears, and (pre)malignant lesions. CADM1 protein expression in cervical tissues was analysed by immunohistochemistry. All statistical tests were two-sided. Density of methylation was associated with the degree of anchorage-independent growth and CADM1 gene silencing in vitro. In cervical squamous lesions, methylation frequency and density increased with severity of disease. Dense methylation (defined as >or= 2 methylated regions) increased from 5% in normal cervical samples to 30% in CIN3 lesions and 83% in squamous cell carcinomas (SCCs) and was significantly associated with decreased CADM1 protein expression (p < 0.00005). The frequency of dense methylation was significantly higher in >or= CIN3 compared with <or= CIN1 (p = 0.005), as well as in SCCs compared with adenocarcinomas (83% versus 23%; p = 0.002). Detection of dense CADM1 promoter methylation will contribute to the assembly of a valuable marker panel for the triage of high-risk HPV-positive women at risk of >or= CIN3. Copyright (c) 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18498117     DOI: 10.1002/path.2367

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  43 in total

1.  Recent findings on epigenetic gene abnormalities involved in uterine cancer.

Authors:  Megumi Yanokura; Kouji Banno; Yusuke Kobayashi; Hiroyuki Nomura; Shigenori Hayashi; Eiichiro Tominaga; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2017-09-20

2.  MYCN-mediated miR-21 overexpression enhances chemo-resistance via targeting CADM1 in tongue cancer.

Authors:  Guopei Zheng; Nan Li; Xiaoting Jia; Cong Peng; Liyun Luo; Yingen Deng; Jiang Yin; Ying Song; Hao Liu; Minying Lu; Zhijie Zhang; Yixue Gu; Zhimin He
Journal:  J Mol Med (Berl)       Date:  2016-04-08       Impact factor: 4.599

3.  Longitudinal assessment of DNA methylation changes during HPVE6E7-induced immortalization of primary keratinocytes.

Authors:  Denise M Schütze; Jan M Kooter; Saskia M Wilting; Chris J L M Meijer; Wim Quint; Peter J F Snijders; Renske D M Steenbergen
Journal:  Epigenetics       Date:  2015-01-23       Impact factor: 4.528

Review 4.  Epigenetics and cervical cancer: from pathogenesis to therapy.

Authors:  Jinchuan Fang; Hai Zhang; Sufang Jin
Journal:  Tumour Biol       Date:  2014-02-20

Review 5.  Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions.

Authors:  Renske D M Steenbergen; Peter J F Snijders; Daniëlle A M Heideman; Chris J L M Meijer
Journal:  Nat Rev Cancer       Date:  2014-06       Impact factor: 60.716

6.  Generation of a monoclonal antibody specific to a new candidate tumor suppressor, cell adhesion molecule 2.

Authors:  Meijin Huang; Ziyuan Xia; Yang Wang; Liang Huang; Qian Ma; Xia Chen; Hao Wang; Bin Lu; Yajun Guo
Journal:  Tumour Biol       Date:  2014-04-30

7.  Methylation-mediated transcriptional repression of microRNAs during cervical carcinogenesis.

Authors:  Saskia M Wilting; Wina Verlaat; Annelieke Jaspers; Nour A Makazaji; Reuven Agami; Chris J L M Meijer; Peter J F Snijders; Renske D M Steenbergen
Journal:  Epigenetics       Date:  2013-01-16       Impact factor: 4.528

8.  Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test.

Authors:  D C Rijkaart; V M H Coupe; F J van Kemenade; D A M Heideman; A T Hesselink; W Verweij; L Rozendaal; R H Verheijen; P J Snijders; J Berkhof; C J L M Meijer
Journal:  Br J Cancer       Date:  2010-08-31       Impact factor: 7.640

9.  Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer.

Authors:  Saskia M Wilting; Robert A A van Boerdonk; Florianne E Henken; Chris J L M Meijer; Begona Diosdado; Gerrit A Meijer; Carlos le Sage; Reuven Agami; Peter J F Snijders; Renske D M Steenbergen
Journal:  Mol Cancer       Date:  2010-06-26       Impact factor: 27.401

10.  hTERT promoter activity and CpG methylation in HPV-induced carcinogenesis.

Authors:  Jillian de Wilde; Jan M Kooter; Renée M Overmeer; Debbie Claassen-Kramer; Chris J L M Meijer; Peter J F Snijders; Renske D M Steenbergen
Journal:  BMC Cancer       Date:  2010-06-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.